A preclinical and clinical review of aflibercept for the management of cancer.
about
AfliberceptCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsMolecularly targeted drugs for metastatic colorectal cancerAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyMolecular therapy of colorectal cancer: progress and future directionsTumor stroma as targets for cancer therapyThe antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.Ziv-aflibercept use in metastatic colorectal cancer.Biological agents in gastrointestinal cancers: adverse effects and their management.Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.Smarter drugs emerging in pancreatic cancer therapy.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updateZiv-aflibercept in metastatic colorectal cancerDll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenograftsEmerging treatment options for management of malignant ascites in patients with ovarian cancer.Aflibercept in pediatric solid tumors: moving beyond the trap.Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statementCompartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.Cancer prevention and therapy through the modulation of the tumor microenvironment.Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.Risk factors and therapeutic targets in pancreatic cancer.Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma.A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.Controlling escape from angiogenesis inhibitors.New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.The VEGF pathway in lung cancer.Aflibercept--a decoy VEGF receptor.Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.Do anti-angiogenic cancer therapies increase risk of significant weight loss?Advances and new perspectives in the treatment of metastatic colon cancer.Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis.Accuracy of TNM staging in colorectal cancer: a review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Aflibercept: A Review in Metastatic Colorectal Cancer.Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.Gene delivery nanoparticles to modulate angiogenesis.Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: a review.Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept.
P2860
Q24600199-C5E24913-DA7C-485F-8C2C-45205FDB7E2CQ26746067-C05013E6-ADB7-4A15-8097-8499FDF72940Q26828735-FA67A157-8DE5-4CC3-BA11-01887AE67C50Q26853604-B2B3E2A2-0A66-4D83-8148-0BDD03F32B19Q27005764-AB34C290-C946-4C95-8309-1BD3C0FA89FCQ27015980-7DAE4FE3-0B47-4C88-9A7B-09BCD5F06FB9Q30409780-AEF10F92-60F6-4D0F-AC51-A48996589D8CQ33886059-A35E86BD-D97F-4116-BD1B-1A4989481A10Q33895581-A44F7E7A-D9F9-43F3-B697-59BCA064A071Q34348270-404BC01B-AD67-430D-91E2-81D85D683850Q34410212-C8B995B8-EAF7-405D-ABC4-C0839E0029F6Q34441837-F687F5F3-0F84-43A8-931A-418358B27AAAQ34658579-A4206EC1-6B55-4A1C-917B-D09F0C452BE1Q35418092-68661756-3BAD-4DB8-A9F6-E2660FBD99C1Q36173084-3CA93BCD-6CB8-4E77-B7BC-062D408EB645Q36243664-BDDAFC72-7CC1-4240-AD96-8A2AB2957798Q37037106-8229E526-39BF-4EED-82C3-135BBA1906F6Q37054876-718188BE-1EF9-4998-91D1-90CC91DD5940Q37058267-23D310FD-926E-45F0-98F5-315F369C2F5CQ37269115-4338D9F9-FF3B-4DF6-ABC7-27B0139EACCBQ37317310-8F35EA5D-0DDD-4C95-A5CF-2161E63E9CDDQ37361541-68810022-F860-4E0D-9835-7CF49CCC2F61Q37396473-CB0D673C-130A-451E-9DAF-C3110AB99806Q37558971-7663627E-4C06-4F43-B421-A8A393F31965Q37672654-5BCF905D-FF27-44C1-9168-1B0F95376049Q38112587-23105557-F4DF-4DBA-80A8-DCF82E3D4279Q38130312-0D5D3BFC-4BB5-4A20-8EF5-180A2B2B24DDQ38148460-63D654ED-0A47-48D6-92FA-A741A4A0B453Q38180313-DB161E55-D431-43CD-8A4B-B662E9A83973Q38184936-7FAEC868-B794-421D-A06E-08C340BAF15AQ38192670-26947F05-9B1D-49A9-8D35-76F70AFB8F1BQ38229589-CD340F60-327E-4352-B9C3-0F3B47437F8AQ38234800-376424FF-E34C-4CD5-BD1E-947FEA98E6A5Q38241953-AB9F5CD7-AAC7-4CCA-9AEE-BC84EE9725D1Q38525073-61ADE17F-5DFD-4283-A1A0-70D5FB8A57E7Q38556642-761A26BD-7ACF-43B4-95C3-9A4E33C34DB1Q38841033-B961AEEF-C28D-4C62-B922-841C644766BAQ39027588-7FAC131F-4F4E-4568-A826-FEF81D78FE54Q42181162-1123537C-BDF8-452D-B0CD-A354ED961615Q42775518-EA904356-BDA7-4FB8-9959-5D1AFF4E9464
P2860
A preclinical and clinical review of aflibercept for the management of cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A preclinical and clinical review of aflibercept for the management of cancer.
@en
A preclinical and clinical review of aflibercept for the management of cancer.
@nl
type
label
A preclinical and clinical review of aflibercept for the management of cancer.
@en
A preclinical and clinical review of aflibercept for the management of cancer.
@nl
prefLabel
A preclinical and clinical review of aflibercept for the management of cancer.
@en
A preclinical and clinical review of aflibercept for the management of cancer.
@nl
P1476
A preclinical and clinical review of aflibercept for the management of cancer.
@en
P2093
Andrew Gaya
Vivien Tse
P304
P356
10.1016/J.CTRV.2011.12.008
P577
2012-01-20T00:00:00Z